Stock Scorecard
Stock Summary for Genfit (GNFT) - $3.44 as of 12/9/2023 10:03:40 AM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GNFT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GNFT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GNFT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for GNFT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for GNFT
Financial Details for GNFT
Company Overview |
|
---|---|
Ticker | GNFT |
Company Name | Genfit |
Country | USA |
Description | Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company is headquartered in Loos, France. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 9/30/2023 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 3.44 |
Last Day Price Updated | 12/9/2023 10:03:40 AM EST |
Last Day Volume | 148,945 |
Average Daily Volume | 17,113 |
52-Week High | 4.75 |
52-Week Low | 2.89 |
Last Price to 52 Week Low | 19.03 % |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 158.38 |
Sector PE | 62.37 |
5-Year Average PE | 12.49 |
Free Cash Flow Ratio | 1.54 |
Industry Free Cash Flow Ratio | 17.89 |
Sector Free Cash Flow Ratio | 31.15 |
Current Ratio Most Recent Quarter | 2.95 |
Total Cash Per Share | 2.24 |
Book Value Per Share Most Recent Quarter | 1.50 |
Price to Book Ratio | 2.13 |
Industry Price to Book Ratio | 4.65 |
Sector Price to Book Ratio | 19.59 |
Price to Sales Ratio Twelve Trailing Months | 5.86 |
Industry Price to Sales Ratio Twelve Trailing Months | 16.60 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.61 |
Share Statistics |
|
Total Shares Outstanding | 49,835,000 |
Market Capitalization | 171,432,400 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Dividend King? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00 % |
5-Year Dividend Payments Count | 0 |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00 % |
Annual Earnings Growth | -135.27 % |
Reported EPS 12 Trailing Months | -0.78 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 0.11 |
Net Income Twelve Trailing Months | 0 |
Net Income Past Year | -23,720,000 |
Net Income Prior Year | 67,259,000 |
Quarterly Revenue Growth YOY | 24.50 % |
5-Year Revenue Growth | 313.62 % |
Balance Sheet |
|
Total Cash Most Recent Quarter | 111,826,000 |
Total Cash Past Year | 136,001,000 |
Total Cash Prior Year | 258,756,000 |
Net Cash Position Most Recent Quarter | 49,177,000 |
Net Cash Position Past Year | 65,806,000 |
Long Term Debt Past Year | 70,195,000 |
Long Term Debt Prior Year | 72,047,000 |
Total Debt Most Recent Quarter | 62,649,000 |
Equity to Debt Ratio Past Year | 0.57 |
Equity to Debt Ratio Most Recent Quarter | 0.54 |
Total Stockholder Equity Past Year | 94,528,000 |
Total Stockholder Equity Prior Year | 119,097,000 |
Total Stockholder Equity Most Recent Quarter | 74,520,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.02 |
MACD Signal | 0.01 |
20-Day Bollinger Lower Band | 2.91 |
20-Day Bollinger Middle Band | 3.41 |
20-Day Bollinger Upper Band | 3.90 |
Beta | 0.89 |
RSI | 60.08 |
50-Day SMA | 3.87 |
200-Day SMA | 5.08 |
System |
|
Modified | 12/9/2023 10:04:26 AM EST |